3D Bioprinting Peptigels to Increase Cell Viability

The challenge

Barrett's esophagus is a condition in which the cells in the esophagus grow abnormally and if it is not treated, it frequently leads to cancer. Esophageal cancer is the 8th most common cancer in the world.

It is possible to manage the disease by eliminating the pre-cancerous cells endoscopically. However, this treatment can also cause healthy cells to become damaged and lead to fibrotic strictures, narrowing the esophagus and resulting in additional challenges for patients.

At the moment, these strictures are managed using endoscopic balloon dilation; however, common side effects include bleeding, perforation and septicemia.

One method to treat this condition is to apply a hydrogel after surgery to encourage healthy regeneration of the esophagus. At present, most hydrogels are drawn from animal sources and as a result are not appropriate for clinical translation. However, PeptiGels® provides a clinically translatable solution.

The science

Researchers at The Universities of Manchester and Nottingham, led by Professor Julie Gough, have investigated PeptiGels® for use in the treatment of these strictures.

These hydrogels have been developed especially to promote cell growth, are completely synthetic and inherently immunogenic and biodegradable, opening up the opportunity for clinic use.

They also contain shear-thinning properties, so they can be sprayed endoscopically directly to the treatment area and their mucoadhesive properties mean they stay at the administration site, ensuring they are the perfect candidates for tissue regenerative scaffolds.

Using Manchester BIOGEL's PeptiGels®, we were able to grow 3D co-cultures of primary esophageal cells with the desired morphology and functionality. These findings are the first step in using these synthetic hydrogels to manage structures caused by endoscopic treatment of Barretts' esophagus.

Julie Gough, Professor of Biomaterials and Tissue Engineering, The University of Manchester

The results

Through the exploration of a library of PeptiGels® (Starter Pack) the optimal hydrogel for the culture of each esophageal cell was discovered; rat esophageal stromal fibroblasts (rOSFs) within the hydrogel (3D) and mouse esophageal epithelial cells (mOECs) on the surface (2D).

Somewhat predictably, the cells responded best to the PeptiGel® with the mechanical properties most alike to native human esophageal tissue, Alpha5; the rOSFs were fibroblastic in appearance and desired mOEC morphology and epithelial sheet formation was detected.

3D Bioprinting Peptigels to Increase Cell Viability

Image Credit: Manchester BIOGEL

Work then progressed to examine a three-dimensional (3D) co-culture system, more representative of in vivo esophageal tissue, utilizing this PeptiGeI®. After a week, this multicellular and multiplayer matrix had successfully supported the creation of a functional, uninterrupted epithelial sheet.

The future

This promising data is now being taken to the next level in order to make further advances towards a new treatment for stricture management in Barrett's esophagus.

About Manchester BIOGEL

Over 15 years ago, Professors Aline Miller and Alberto Saiani at The University of Manchester synthesised a self-assembling oligo-peptide with interesting gelation properties. This work started with a small grant from the University.

Over subsequent years, the team meticulously crafted and studied self-assembling peptides to perfect their platform technology and produce a range of hydrogels ideal for 3D cell culture. In 2014, due to a demand for their materials, our company, Manchester BIOGEL was founded to enable these hydrogels to be readily available to researchers wishing to create new opportunities in the high-growth fields of 3D cell culture, 3D bioprinting and medical devices. Since opening our doors, we have supported scientists in the UK and beyond to create optimal environments for a wide variety of cell types.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Mar 11, 2020 at 4:31 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Manchester BIOGEL. (2020, March 11). 3D Bioprinting Peptigels to Increase Cell Viability. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/whitepaper/20200311/3D-Bioprinting-Peptigels-to-Increase-Cell-Viability.aspx.

  • MLA

    Manchester BIOGEL. "3D Bioprinting Peptigels to Increase Cell Viability". News-Medical. 22 December 2024. <https://www.news-medical.net/whitepaper/20200311/3D-Bioprinting-Peptigels-to-Increase-Cell-Viability.aspx>.

  • Chicago

    Manchester BIOGEL. "3D Bioprinting Peptigels to Increase Cell Viability". News-Medical. https://www.news-medical.net/whitepaper/20200311/3D-Bioprinting-Peptigels-to-Increase-Cell-Viability.aspx. (accessed December 22, 2024).

  • Harvard

    Manchester BIOGEL. 2020. 3D Bioprinting Peptigels to Increase Cell Viability. News-Medical, viewed 22 December 2024, https://www.news-medical.net/whitepaper/20200311/3D-Bioprinting-Peptigels-to-Increase-Cell-Viability.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.